Abstract
Pre-eclampsia results in real risk and significant impact on indicators related to maternal and child health. The only known treatment is delivery of the fetus and placenta. Despite intensive research, the causes of PE remain to be elucidated. It is suggested that pre-eclampsia is caused by a global maternal inflammatory response to a damaged placenta. Besides inflammation, cytotoxic and apoptotic mechanisms are also implicated in the pathogenesis of pre-eclampsia. Considering the importance of apoptosis to pre-eclampsia genesis, the aim of this study was to determine the frequencies of the genotypes for FAS gene polymorphisms (rs3740286 and rs4064) and to associate these with pre-eclampsia development. Women with and without pre-eclampsia were investigated. Accordingly, peripheral blood was collected, and DNA extracted, followed by genotyping using Real-time PCR with hydrolysis probe. The results showed no association between genotypes and pre-eclampsia development for both polymorphisms studied (χ2=3.39; p=.177, for rs3740286 and χ2=0.119; p=.94 for rs4064). Women with familiar history of pre-eclampsia and primiparity showed more probability to develop the condition, by multiple logistic regression analysis (OR=8.61, CI=3.39-21.86, p<0.0001; OR=6.64. CI=2.94-14.99, p<0.0001, respectively). It seems that FAS gene polymorphisms (rs3740286 and rs4064) might not be important candidates for the development of pre-eclampsia.
Highlights
Pre-eclampsia (PE) results in real risk and significant impact on indicators related to maternal and child health (Ramos et al 2017)
Genetic and environmental factors are involving in its pathogenesis and pathophysiology
The other group was the pre-eclampsia one, consisting of 73 (28.6%) pregnant women with pre-eclampsia diagnosed according to the Report of the American National High Blood Pressure Education Program (American College of Obstetricians and Gynecologists 2013); the age range was 18-43 years, and the number range of pregnancies was 1-9
Summary
Pre-eclampsia (PE) results in real risk and significant impact on indicators related to maternal and child health (Ramos et al 2017). The incidence of PE worldwide is about 3-5% of pregnancies. In Brazil, a systematic review identified an incidence of 1.5% for PE (Abalos et al 2013). It originates in the placenta and causes variable maternal and fetal problems (Redman & Sargent 2010). Genetic and environmental factors are involving in its pathogenesis and pathophysiology. The only known treatment is delivery of the fetus and placenta (Romero & Chaiworapongsa 2013). The causes of PE remain to be elucidated (Sziller 2018)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
